8 research outputs found

    Molecular characterization of the human COQ5 C-methyltransferase in coenzyme Q10 biosynthesis

    Get PDF
    Under a Creative Commons license.Coq5 catalyzes the only C-methylation involved in the biosynthesis of coenzyme Q (Q or ubiquinone) in humans and yeast Saccharomyces cerevisiae. As one of eleven polypeptides required for Q production in yeast, Coq5 has also been shown to assemble with the multi-subunit complex termed the CoQ-synthome. In humans, mutations in several COQ genes cause primary Q deficiency, and a decrease in Q biosynthesis is associated with mitochondrial, cardiovascular, kidney and neurodegenerative diseases. In this study, we characterize the human COQ5 polypeptide and examine its complementation of yeast coq5 point and null mutants. We show that human COQ5 RNA is expressed in all tissues and that the COQ5 polypeptide is associated with the mitochondrial inner membrane on the matrix side. Previous work in yeast has shown that point mutations within or adjacent to conserved COQ5 methyltransferase motifs result in a loss of Coq5 function but not Coq5 steady state levels. Here, we show that stabilization of the CoQ-synthome within coq5 point mutants or by over-expression of COQ8 in coq5 null mutants permits the human COQ5 homolog to partially restore coq5 mutant growth on respiratory media and Q6 content. Immunoblotting against the human COQ5 polypeptide in isolated yeast mitochondria shows that the human Coq5 polypeptide migrates in two-dimensional blue-native/SDS-PAGE at the same high molecular mass as other yeast Coq proteins. The results presented suggest that human and Escherichia coli Coq5 homologs expressed in yeast retain C-methyltransferase activity but are capable of rescuing the coq5 yeast mutants only when the CoQ-synthome is assembled.Open Access funded by Telethon (Italy).Peer Reviewe

    Study of the dynamic and function of heterochromatin protein 1 gamma (HP1 gamma) during the process of cell differentiation

    No full text
    La diferenciación celular es un proceso complejo en el cuál un grupo específico de genes se activa y el resto permanece silenciado. HP1γ se asocia a genes activos, pero se desconoce su rol durante la diferenciación celular. En los preadipocitos HP1γ localiza tanto en heterocomo eucromatina, pero cuando se induce la diferenciación HP1γ rápidamente se concentra en un polo del núcleo excluyéndose de regiones heterocromáticas. La polarización de HP1γ no se observa en células que no se diferencian. La fosforilación de HP1γ en Ser93 se induce durante la adipogénesis y también se localiza polarizadamente. La polarización de HP1γ depende de la transcripción, de la integridad del RNA y DNA, y de la señalización por PKA. Interesantemente, marcas epigenéticas que marcan activa transcripción y la RNA pol II colocalizan con HP1γ en dicho polo nuclear. Este dominio muestra altos niveles de incorporación de BrUTP y de acumulación de mRNAs. La inhibición de HP1γ con siRNAs disminuye la incorporación de BrUTP y la expresión de marcadores de diferenciación adipocítica. Este dinámico patrón nuclear polarizado no se ha descripto antes, y proponemos que podría constituir un nuevo mecanismo para regular la expresión de genes requeridos durante el inicio de la diferenciación celular.Cell differentiation is a complex process in which a specific subset of genes is activated while the rest of genes are silenced. HP1γ is associated to actively transcribed genes, however little is known about its role during cell differentiation. In preadipocytes HP1γ localizes in heterochromatic and euchromatic domains, but when preadipocytes are induced to differentiate HP1γ rapidly concentrates in one pole of the nucleus being transiently excluded from heterochromatin. HP1γ polarization is not observed in cells that do not differentiate. HP1γ PSer93 is induced upon adipogenesis and also concentrates in a polarized manner. HP1γ polarization depends on transcription, RNA and DNA integrity, and on PKA signalling. Noteworthy, epigenetic marks that correlate with active transcription and RNA polymerase II co-localizes with HP1γ in the nuclear pole. This domain shows high level of BrUTP incorporation and mRNAs accumulation. Knock down of HP1γ by siRNAs causes a decrease in BrUTP incorporation and a decrease in the expression of markers of adipocyte differentiation. Importantly, to our knowledge this dynamic nuclear polarization has not been described before, and we propose that it may constitute a novel mechanism for regulating the expression of a determined subset of genes required during the initial steps of cell differentiation.Fil:Desbats, María Andrea. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina

    The COQ2 genotype predicts the severity of Coenzyme Q10 deficiency

    No full text
    et al.COQ2 (p-hydroxybenzoate polyprenyl transferase) encodes the enzyme required for the second step of the final reaction sequence of Coenzyme Q10 (CoQ) biosynthesis. Its mutations represent a frequent cause of primary CoQ deficiency and have been associated with the widest clinical spectrum, ranging from fatal neonatal multisystemic disease to late-onset encephalopathy. However, the reasons of this variability are still unknown. We have characterized the structure of human COQ2, defined its subcellular localization and developed a yeast model to validate all the mutant alleles reported so far. Our findings show that the main functional transcript of COQ2 is shorter than what was previously reported and that its protein product localizes to mitochondria with the C-terminus facing the intermembrane space. Complementation experiments in yeast showed that the residual activity of the mutant proteins correlates with the clinical phenotypes observed in patients. We defined the structure of COQ2 with relevant implications for mutation screening in patients and demonstrated that, contrary to other COQ gene defects such as ADCK3, there is a correlation between COQ2 genotype and patient's phenotype.This work was supported by the Italian Ministry of Health [GR2009-1578914 to E.T.]; University of Padova [CPDA140508/14 to E.T.]; Telethon Italy [GGP13222, GGP14187 to L.S.] and by Fondazione CARIPARO [to L.S.].Peer Reviewe

    Mammalian Staufen 1 is recruited to stress granules and impairs their assembly

    Get PDF
    Stress granules are cytoplasmic mRNA-silencing foci that form transiently during the stress response. Stress granules harbor abortive translation initiation complexes and are in dynamic equilibrium with translating polysomes. Mammalian Staufen 1 (Stau1) is a ubiquitous double-stranded RNA-binding protein associated with polysomes. Here, we show that Stau1 is recruited to stress granules upon induction of endoplasmic reticulum or oxidative stress as well in stress granules induced by translation initiation blockers. We found that stress granules lacking Stau1 formed in cells depleted of this molecule, indicating that Stau1 is not an essential component of stress granules. Moreover, Stau1 knockdown facilitated stress granule formation upon stress induction. Conversely, transient transfection of Stau1 impaired stress granule formation upon stress or pharmacological initiation arrest. The inhibitory capacity of Stau1 mapped to the amino-terminal half of the molecule, a region known to bind to polysomes. We found that the fraction of polysomes remaining upon stress induction was enriched in Stau1, and that Stau1 overexpression stabilized polysomes against stress. We propose that Stau1 is involved in recovery from stress by stabilizing polysomes, thus helping stress granule dissolution

    Primary coenzyme Q10 deficiency presenting as fatal neonatal multiorgan failure

    No full text
    Coenzyme Q10 deficiency is a clinically and genetically heterogeneous disorder, with manifestations that may range from fatal neonatal multisystem failure, to adult-onset encephalopathy. We report a patient who presented at birth with severe lactic acidosis, proteinuria, dicarboxylic aciduria, and hepatic insufficiency. She also had dilation of left ventricle on echocardiography. Her neurological condition rapidly worsened and despite aggressive care she died at 23 h of life. Muscle histology displayed lipid accumulation. Electron microscopy showed markedly swollen mitochondria with fragmented cristae. Respiratory-chain enzymatic assays showed a reduction of combined activities of complex I+III and II+III with normal activities of isolated complexes. The defect was confirmed in fibroblasts, where it could be rescued by supplementing the culture medium with 10 μM coenzyme Q10. Coenzyme Q10 levels were reduced (28% of controls) in these cells. We performed exome sequencing and focused the analysis on genes involved in coenzyme Q10 biosynthesis. The patient harbored a homozygous c.545T>G, p.(Met182Arg) alteration in COQ2, which was validated by functional complementation in yeast. In this case the biochemical and morphological features were essential to direct the genetic diagnosis. The parents had another pregnancy after the biochemical diagnosis was established, but before the identification of the genetic defect. Because of the potentially high recurrence risk, and given the importance of early CoQ10 supplementation, we decided to treat with CoQ10 the newborn child pending the results of the biochemical assays. Clinicians should consider a similar management in siblings of patients with CoQ10 deficiency without a genetic diagnosis.This work was supported by grants from Fondazione CARIPARO, Telethon Italy GGP13222 and University of Padova (CPDA123573/12) to LS; Telethon Italy GGP10121 and PRIN 20108WT59Y_003 to OZ; Italian Ministry of Health (GR-2009-1578914) to ET; Spanish FIS grant PI11-00078 and Proyecto Excelencia P08-CTS-03988 to PN.Peer Reviewe

    Mutations in COQ8B (ADCK4) found in patients with steroid-resistant nephrotic syndrome alter COQ8B function

    No full text
    © 2017 The Authors.Mutations in COQ8B cause steroid-resistant nephrotic syndrome with variable neurological involvement. In yeast, COQ8 encodes a protein required for coenzyme Q (CoQ) biosynthesis, whose precise role is not clear. Humans harbor two paralog genes: COQ8A and COQ8B (previously termed ADCK3 and ADCK4). We have found that COQ8B is a mitochondrial matrix protein peripherally associated with the inner membrane. COQ8B can complement a ΔCOQ8 yeast strain when its mitochondrial targeting sequence (MTS) is replaced by a yeast MTS. This model was employed to validate COQ8B mutations, and to establish genotype–phenotype correlations. All mutations affected respiratory growth, but there was no correlation between mutation type and the severity of the phenotype. In fact, contrary to the case of COQ2, where residual CoQ biosynthesis correlates with clinical severity, patients harboring hypomorphic COQ8B alleles did not display a different phenotype compared with those with null mutations. These data also suggest that the system is redundant, and that other proteins (probably COQ8A) may partially compensate for the absence of COQ8B. Finally, a COQ8B polymorphism, present in 50% of the European population (NM_024876.3:c.521A > G, p.His174Arg), affects stability of the protein and could represent a risk factor for secondary CoQ deficiencies or for other complex traits.Fondazione CARIPARO; IRP Fondazione Città della Speranza; Italian Ministry of Health (GR-2009-1578914); University of Padova (CPDA140508/14). Communicated by Daniel W. Neber

    Vanillic Acid Restores Coenzyme Q Biosynthesis and ATP Production in Human Cells Lacking COQ6

    No full text
    12 Páginas.-- 6 FigurasCoenzyme Q (CoQ), a redox-active lipid, is comprised of a quinone group and a polyisoprenoid tail. It is an electron carrier in the mitochondrial respiratory chain, a cofactor of other mitochondrial dehydrogenases, and an essential antioxidant. CoQ requires a large set of enzymes for its biosynthesis; mutations in genes encoding these proteins cause primary CoQ deficiency, a clinically and genetically heterogeneous group of diseases. Patients with CoQ deficiency often respond to oral CoQ10 supplementation. Treatment is however problematic because of the low bioavailability of CoQ10 and the poor tissue delivery. In recent years, bypass therapy using analogues of the precursor of the aromatic ring of CoQ has been proposed as a promising alternative. We have previously shown using a yeast model that vanillic acid (VA) can bypass mutations of COQ6, a monooxygenase required for the hydroxylation of the C5 carbon of the ring. In this work, we have generated a human cell line lacking functional COQ6 using CRISPR/Cas9 technology. We show that these cells cannot synthesize CoQ and display severe ATP deficiency. Treatment with VA can recover CoQ biosynthesis and ATP production. Moreover, these cells display increased ROS production, which is only partially corrected by exogenous CoQ, while VA restores ROS to normal levels. Furthermore, we show that these cells accumulate 3-decaprenyl-1,4-benzoquinone, suggesting that in mammals, the decarboxylation and C1 hydroxylation reactions occur before or independently of the C5 hydroxylation. Finally, we show that COQ6 isoform c (transcript NM_182480) does not encode an active enzyme. VA can be produced in the liver by the oxidation of vanillin, a nontoxic compound commonly used as a food additive, and crosses the blood-brain barrier. These characteristics make it a promising compound for the treatment of patients with CoQ deficiency due to COQ6 mutations.This work was funded by Fondazione Telethon Grant 14187c (to L.S.), by grants from Fondazione IRP Città della Speranza (to L.S., E.T., and M.C.), by Fondation pour la Recherche Médicale (grant number “DPM20121125553”), by Agence Nationale de la Recherche grant pABACoQ “ANR-11-JSV8-002” (to F.P.), by Instituto de Salud Carlos III PI17/01286 FIS grant, by Junta de Andalucí a Proyecto de Excelencia CTS943, and by the EU FEDER program (to P.N.).Peer reviewe
    corecore